Syngene International Limited — PPTs, 09-09-2025: Investor Presentation

Syngene boosted its growth by acquiring a multimodal biologics facility (Unit-3) in Dec 2023 for ₹617 Cr ($75 Mn). This strategic move significantly enhances its CRDMO capabilities, adding 20 KL drug substance capacity and crucial commercial fill-finish lines. Unit-3 began partial operations in Q1 FY26, already delivering a GMP clinical batch for a US client. Management forecasts positive PAT contribution from FY27 and operating margins aligning with company average by FY29. Total operationalization cost, including ₹100 Cr for modifications, stands at $85 Mn. Syngene's focus remains on integrated projects across human and animal health, driving cost efficiency through innovation.